Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of “Buy” from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is $78.00.

Several research analysts have issued reports on the company. Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective on the stock. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock. Finally, HC Wainwright reduced their price objective on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Monday.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Aberdeen Group plc lifted its stake in shares of Structure Therapeutics by 45.2% in the 1st quarter. Aberdeen Group plc now owns 248,899 shares of the company’s stock valued at $4,308,000 after purchasing an additional 77,511 shares during the period. Invesco Ltd. lifted its stake in shares of Structure Therapeutics by 6.1% in the 1st quarter. Invesco Ltd. now owns 394,386 shares of the company’s stock valued at $6,827,000 after purchasing an additional 22,619 shares during the period. National Bank of Canada FI increased its position in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after buying an additional 2,766 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company’s stock valued at $74,000 after buying an additional 3,213 shares in the last quarter. Finally, Readystate Asset Management LP increased its position in shares of Structure Therapeutics by 129.9% in the 1st quarter. Readystate Asset Management LP now owns 481,241 shares of the company’s stock valued at $8,330,000 after buying an additional 271,899 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $23.89 on Wednesday. The firm has a market cap of $1.37 billion, a PE ratio of -32.28 and a beta of -1.69. Structure Therapeutics has a one year low of $13.22 and a one year high of $62.74. The stock’s 50 day simple moving average is $20.98 and its 200 day simple moving average is $26.75.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). As a group, equities analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.